Drug intelligence / Profile preview

emaxitinib

Development stage: Unknown
Lead developer: Ruishi Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Emaxitinib is an orally administered, highly selective small molecule Janus kinase 1 (JAK1) inhibitor. Developed by Ruishi Biologics, a subsidiary of Hengrui Pharmaceutical, it targets the JAK-STAT signaling pathway, which is involved in inflammatory and immune responses. It is being investigated for the treatment of autoimmune diseases, with a completed Phase III clinical trial for atopic dermatitis.

Other names: Ivarmacitinib tablet艾玛昔替尼

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on emaxitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emaxitinib.

Explore the full profile